Survanta 25 mg/mL

Survanta 25 mg/mL is a suspension form of beractant, used for respiratory support in premature infants. This single-use vial is designed for endotracheal administration, providing essential lung surfactant therapy.

Survanta 25 mg/mL is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. Survanta provides exogenous surfactant replacement, aiding in lung function and oxygenation. It is administered directly into the trachea to help infants breathe more easily.

Survanta 25 mg/mL works by replacing natural lung surfactant, which helps reduce surface tension in the alveoli. This action can improve lung compliance and gas exchange, making it easier for premature infants to breathe. The effects are typically observed soon after administration, supporting respiratory stability.

Survanta 25 mg/mL should be handled with care, ensuring proper aseptic techniques during administration. It is intended for single-use only and should not be reused. Always follow healthcare provider instructions for storage and administration to maintain product integrity and safety.

Survanta 25 mg/mL may interact with other medications administered via the endotracheal route. It is important to consult with a healthcare provider to manage potential interactions. Additionally, ensure compatibility with any other respiratory support therapies being used concurrently.